Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma

Leukemia volume 21, pages 169–174 (2007)Cite this article

Abstract

CD307 is a differentiation antigen expressed in B-lineage cells. One soluble and two membrane-bound forms have been predicted and an enzyme-linked immunosorbent assay (ELISA) for soluble CD307 established. Our goal was to determine if CD307 is expressed on the surface of cells from patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and other B-cell malignancies and if soluble CD307 levels are elevated in the blood of patients with these B-cell malignancies. Cells and blood were collected from patients. Expression of CD307 was measured by flow cytometry and blood levels of soluble CD307 by ELISA. High soluble CD307 levels were detected in 21/43 (49%) of patients with MM, 36/46 (78%) with CLL and 9/24 (38%) with MCL. Soluble CD307 levels correlated with plasma cell percentages in bone marrow aspirates in MM and total white blood cells in CLL. CD307 on the cell membrane was detected by flow cytometry in 8/8 MM, 23/29 CLL and 4/5 MCL samples. Because CD307 is present on malignant cells from patients with MM, CLL and MCL, CD307 may be a useful therapeutic target for the treatment of these diseases.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Hatzivassiliou G, Miller I, Takizawa J, Palanisamy N, Rao PH, Iida S et al. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity 2001; 14: 277–289.

    Article  CAS  PubMed  Google Scholar 

  2. Davis RS, Dennis Jr G, Odom MR, Gibson AW, Kimberly RP, Burrows PD et al. Fc receptor homologs: newest members of a remarkably diverse Fc receptor gene family. Immunol Rev 2002; 190: 123–136.

    Article  CAS  PubMed  Google Scholar 

  3. Davis RS, Dennis Jr G, Kubagawa H, Cooper MD . Fc receptor homologs (FcRH1-5) extend the Fc receptor family. Curr Top Microbiol Immunol 2002; 266: 85–112.

    CAS  PubMed  Google Scholar 

  4. Guselnikov SV, Ershova SA, Mechetina LV, Najakshin AM, Volkova OY, Alabyev BY et al. A family of highly diverse human and mouse genes structurally links leukocyte FcR, gp42 and PECAM-1. Immunogenetics 2002; 54: 87–95.

    Article  CAS  PubMed  Google Scholar 

  5. Mechetina LV, Najakshin AM, Volkova OY, Gueslnikov SV, Faizulin RZ, Alabyev BY et al. FCRL, a novel member of the leukocyte Fc receptor family possesses unique structural features. Eur J Immunol 2002; 32: 87–96.

    Article  CAS  PubMed  Google Scholar 

  6. Miller I, Hatzivassiliou G, Cattoretti G, Mendelsohn C, Dalla-Favera R . IRTAs: a new family of immunoglobulinlike receptors differentially expressed in B cells. Blood 2002; 99: 2662–2669.

    Article  CAS  PubMed  Google Scholar 

  7. Nakayama Y, Weissman SM, Bothwell AL . BXMAS1 identifies a cluster of homologous genes differentially expressed in B cells. Biochem Biophys Res Commun 2001; 285: 830–837.

    Article  CAS  PubMed  Google Scholar 

  8. Davis RS, Ehrhardt GR, Leu CM, Hirano M, Cooper MD . An extended family of Fc receptor relatives. Eur J Immunol 2005; 35: 674–680.

    Article  CAS  PubMed  Google Scholar 

  9. Davis RS, Wang YH, Kubagawa H, Cooper MD . Identification of a family of Fc receptor homologs with preferential B cell expression. Proc Natl Acad Sci USA 2001; 98: 9772–9777.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Davis RS, Stephan RP, Chen CC, Dennis Jr G, Cooper MD . Differential B cell expression of mouse Fc receptor homologs. Int Immunol 2004; 16: 1343–1353.

    Article  CAS  PubMed  Google Scholar 

  11. Ise T, Maeda H, Santora K, Xiang L, Kreitman RJ, Pastan I et al. Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies. Clin Cancer Res 2005; 11: 87–96.

    CAS  PubMed  Google Scholar 

  12. Vidal-Laliena M, Romero X, March S, Requena V, Petriz J, Engel P . Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry. Cell Immunol 2005; 236: 6–16.

    Article  CAS  PubMed  Google Scholar 

  13. Zola H, Swart B, Nicholson I, Aasted B, Bensussan A, Boumsell L et al. CD molecules 2005: human cell differentiation molecules. Blood 2005; 106: 3123–3126.

    Article  CAS  PubMed  Google Scholar 

  14. Ise T, Kreitman RJ, Pastan I, Nagata S . Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera. Clin Chem Lab Med 2006; 44: 594–602.

    Article  CAS  PubMed  Google Scholar 

  15. Hooper NM, Karran EH, Turner AJ . Membrane protein secretases. Biochem J 1997; 321: 265–279.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Solberg H . Establishment and use of reference values. In: Buritis C, Ashwood E, Bruns D (eds) Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. St Louis: Saunders, 2006, 425–448.

    Google Scholar 

  17. Linnet K . Nonparametric estimation of reference intervals by simple and bootstrap-based procedures. Clin Chem 2000; 46: 867–869.

    CAS  PubMed  Google Scholar 

  18. Helsel DR . Nondetects and Data Analysis. John Wiley & Sons: NJ, 2005, 1–268.

    Google Scholar 

  19. Ahmad E, Kingma DW, Jaffe ES, Schrager JA, Janik J, Wilson W et al. Flow cytmetric immunophenotypic profiles of mature gamma delta T-cell malignancies involving peripheral blood and bone marrow. Cytometry B Clin Cytom 2005; 67: 6–12.

    Article  PubMed  Google Scholar 

  20. Wierda WG, Kipps TJ, Keating MJ . Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 6325–6332.

    Article  CAS  PubMed  Google Scholar 

  21. Ghielmini M, Schmitz SFH, Cogliatti S, Bertoni F, Waltzer U, Fey MF et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss group for clinical cancer research (SAKK). J Clin Oncol 2005; 23: 705–711.

    Article  CAS  PubMed  Google Scholar 

  22. Nagata S, Ise T, Onda M, Nakamura K, Ho M, Raubitschek A et al. Cell membrane-specific epitopes on CD30: potentially superior targets for immunotherapy. Proc Natl Acad Sci USA 2005; 102: 7946–7951.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392.

    CAS  PubMed  Google Scholar 

  24. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 2000; 13: 193–207.

    Article  CAS  PubMed  Google Scholar 

  25. Lu P . Staging and classification of lymphoma. Semin Nucl Med 2005; 35: 160–164.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

Author information

Author notes

  1. T Ise and S Nagata: These authors contributed equally to this work.

Authors and Affiliations

  1. Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    T Ise, S Nagata, R J Kreitman & I Pastan

  2. Medical Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    W H Wilson

  3. Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    A S Wayne

  4. Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    M Stetler-Stevenson

  5. Experimental Transplantation & Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    M R Bishop

  6. Experimental Therapeutics Center, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    D A Scheinberg

  7. Hematology/Oncology Division, Department of Medicine, Moores UCSD Cancer Center, University of California, San Diego, LaJolla, CA, USA

    L Rassenti & T J Kipps

  8. Laboratory Medicine and Pathology, Genomics Research Center, Mayo Clinic College of Medicine, Rochester, MN, USA

    R A Kyle & D F Jelinek

Authors
  1. T Ise
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Nagata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R J Kreitman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W H Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A S Wayne
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Stetler-Stevenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M R Bishop
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D A Scheinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L Rassenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. T J Kipps
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R A Kyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. D F Jelinek
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. I Pastan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I Pastan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ise, T., Nagata, S., Kreitman, R. et al. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia 21, 169–174 (2007). https://doi.org/10.1038/sj.leu.2404445

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404445

Keywords

This article is cited by

Search

Advanced search

Quick links